The T2DM participants were taking diabetes medications at the time of the study that varied in their nature, and it is possible that these different medications affected their insulin and C-peptide responses in the MTT, especially in the patients with a sulphonylurea. The gene discussed is INS; the disease is diabetes mellitus.